These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 2256066)

  • 21. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
    Rabbani A; Alexander GC
    Am J Hypertens; 2008 May; 21(5):509-13. PubMed ID: 18437141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thoracic aortic aneurysm repair. Direct hospital cost and Diagnosis Related Group reimbursement.
    Mishra V; Geiran O; Krohg-Sørensen K; Andresen S
    Scand Cardiovasc J; 2008 Feb; 42(1):77-84. PubMed ID: 18273734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ectopic pregnancy in the United States: economic consequences and payment source trends.
    Washington AE; Katz P
    Obstet Gynecol; 1993 Feb; 81(2):287-92. PubMed ID: 8423966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: analysis of the Belgian national database.
    van Driel ML; Vander Stichele R; Elseviers M; De Sutter A; De Maeseneer J; Christiaens T
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1113-22. PubMed ID: 18823069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes.
    Swinburn B; Milne RJ; Richards M; Begg E; Foote S; Jackson R
    N Z Med J; 2000 Oct; 113(1119):425-8. PubMed ID: 11127362
    [No Abstract]   [Full Text] [Related]  

  • 28. A study of the additional costs of dispensing workers' compensation prescriptions.
    Schafermeyer KW
    Res Social Adm Pharm; 2007 Mar; 3(1):123-36. PubMed ID: 17350561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of capitation rates for prescription medication benefits from an insurance perspective.
    Lawson KA
    Benefits Q; 1991; 7(3):52-61. PubMed ID: 10117172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug expenditures of pensioners in 1997-2000].
    Swistak P; Błońska-Fajfrowska B
    Wiad Lek; 2003; 56(1-2):85-8. PubMed ID: 12901276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Copayments for medications. Final rule.
    Department of Veterans Affairs
    Fed Regist; 2001 Dec; 66(235):63449-51. PubMed ID: 11778627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health Care Financing Administration: Pharmaceutical Reimbursement Board; final maximum allowable cost determinations.
    Fed Regist; 1979 Aug; 44(169):50651-6. PubMed ID: 10297564
    [No Abstract]   [Full Text] [Related]  

  • 33. Distribution and cost of drugs in a pharmaceutically decentralized health maintenance organization.
    Hardigan WD; Slywka GW; Eng HJ
    Contemp Pharm Pract; 1980; 3(1):23-30. PubMed ID: 10245109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health care cost control by third party payors: fee schedules and the Sherman Act.
    Kallstrom DW
    Duke Law J; 1978 May; (2):645-97. PubMed ID: 10239068
    [No Abstract]   [Full Text] [Related]  

  • 36. Payments, promotion, and the purple pill.
    Ridley DB
    Health Econ; 2015 Jan; 24(1):86-103. PubMed ID: 25491652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Insulin consumption in Norway 1975-89. How much did the change to insulin 100 cost?].
    Berg C; Jervell J
    Tidsskr Nor Laegeforen; 1991 Feb; 111(4):471-3. PubMed ID: 2006490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reimbursement methods for pharmaceutical service.
    Gagnon JP; Rodowskas CA
    J Am Pharm Assoc; 1974 Dec; 14(12):675-8. PubMed ID: 4436520
    [No Abstract]   [Full Text] [Related]  

  • 39. [Price control on drugs in Norway].
    Halse M
    Nord Med; 1975 Mar; 90(3):92-3. PubMed ID: 1153264
    [No Abstract]   [Full Text] [Related]  

  • 40. [Letter: Prescribing of expensive drugs].
    Fenner O
    MMW Munch Med Wochenschr; 1975 Feb; 117(9):362. PubMed ID: 804648
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.